Clinical trials: Chronic Coronary Disease
Chronic Coronary Syndrome, Heart Failure
COVID-19 Related Lockdown Effects On Chronic Diseases
The containment associated with the VIDOC-19 pandemic creates an unprecedented societal situation of physical and social isolation.
- Conditions
- Chronic Coronary Syndrome, Heart Failure, AMD and Macular Edema, Chronic Respiratory Failure
- Trial name
- CLEO-CD (NCT04390126)
- Testing
- life questionnaires, questionnaire
- Where
- France
- Volunteers
- 1,343 people
- Sponsor
- Centre Hospitalier Universitaire Dijon
Coronary Disease, Coronary Arteriosclerosis
Effects of a Healthy Nordic Diet on Atherosclerosis in Patients with Coronary Heart Disease
Diet can play a key role in atherosclerosis and coronary heart disease (CHD), but little interventional data exists, and the mediators of possible anti-atherosclerotic effects of diet are unclear.
- Conditions
- Coronary Disease, Coronary Arteriosclerosis, Myocardial Infarction, Chronic Coronary Syndrome
- Trial name
- NORDHEART (NCT06701968)
- Testing
- Healthy Nordic Diet, Usual Care
- Where
- Sweden
- Volunteers
- 150 people
- Sponsor
- Uppsala University
Heart Failure
Cohort Study of Chronic Heart Failure
The goal of this observational study is to learn about the influencing factors of chronic heart failure prognosis in heart failure patients.
- Trial name
- CHF (NCT05960890)
- Testing
- Remote monitoring assisted by community physicians
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Jiangsu Taizhou People's Hospital
Heart Failure
Assessment of Physical Activity and Cardiovascular Outcomes in Patients With Chronic Heart Failure
SOPHIE is a prospective, multicentre, observational cohort study aiming to enrol 2,000 CHF patients. Baseline assessments include validated PA questionnaires (GPAQ, IPAQ, KCCQ) and seven-day step counts from commercially…
- Trial name
- SOPHIE (NCT07460531)
- Where
- 2 sites in Germany, Italy
- Volunteers
- 2,000 people
- Sponsor
- LMU Klinikum
Chronic Stable Angina
Phase IIb Study of STA-2 in Patients With Chronic Stable Angina
The objective of this study is to evaluate the dose-response of three different dose levels of STA-2 (900 mg daily, 1800 mg daily and 2700 mg daily for 42 days) versus placebo in patients with chronic stable angina.
- Trial name
- NCT01239511
- Testing
- green tea polyphenols (STA-2)
- Where
- 5 sites in Taiwan
- Volunteers
- 186 people
- Sponsor
- Sinphar Pharmaceutical Co., Ltd
Coronary Artery Diseases
BIOFLOW III Satellite-Italy Orsiro Stent System
Clinical evaluation of the Orsiro LESS in subjects requiring coronary revascularization with Drug Eluting Stents (DES). 500 subjects will be enrolled in this registry.
- Trial name
- NCT02028728
- Where
- 18 sites in Italy
- Volunteers
- 609 people
- Sponsor
- Biotronik Italia S.p.A.
Diabetic Nephropathies, Kidney Failure, Chronic
Sotagliflozin to Slow Kidney Function Decline in Persons With Type 1 Diabetes and Diabetic Kidney Disease
Powerful new drugs that can prevent or delay end stage kidney disease (ESKD) - so called sodium-glucose cotransporter-2 inhibitors (SGLT2i) - are now available for patients with type 2 diabetes.
- Conditions
- Diabetic Nephropathies, Kidney Failure, Chronic, Diabetes Mellitus Type 1, Heart Failure
- Trial name
- SUGARNSALT (NCT06217302)
- Testing
- Sotagliflozin
- Where
- 19 sites in United States, Canada
- Volunteers
- 150 people
- Sponsor
- Alessandro Doria
Chronic Obstructive Airway Disease
Cardiac Hemodynamics in Overlap Syndrome (COPD With Obstructive Sleep Apnea)
Patients with both sleep apnea and COPD have overlap syndrome, but their optimal management is not known. We plan to conduct a randomized trial of of bi-level PAP vs.
- Trial name
- NCT01261377
- Testing
- Bi-level positive airway pressure (BPAP), Oxygen, CPAP
- Where
- 2 sites in United States
- Sponsor
- Brigham and Women's Hospital
Heart Arrest, Cardiac Arrest
An Intervention for Cardiac Arrest Survivors With Chronic Fatigue
The primary aim was to examine the feasibility of an Energy Conservation + Problem Solving Therapy (EC+PST) intervention delivered over the telephone and to evaluate the preliminary intervention effect on fatigue impact in daily…
- Conditions
- Heart Arrest, Cardiac Arrest, Fatigue
- Trial name
- CAF (NCT02864719)
- Testing
- Energy Conservation+Problem Solving Therapy
- Volunteers
- 18 people
- Sponsor
- University of Pittsburgh
Type 2 Diabetes, Coronary Heart Disease
NMR Metabolomics-Based Risk Assessment and Stratified Digital Health Interventions in Middle-Aged Adults (PREMAP)
PREMAP invites residents of the Eloisa region (South Savo, Finland) turning 45, 50, or 55 years of age in 2026 to undergo a blood-based NMR metabolomics risk assessment for five interlinked cardio-renal-metabolic conditions (type…
- Conditions
- Type 2 Diabetes, Coronary Heart Disease, Myocardial Infarction, Cerebrovascular Disease
- Trial name
- PREMAP (NCT07820800)
- Testing
- Digital health interventions
- Where
- Finland
- Volunteers
- 1,400 people, healthy volunteers welcome
- Sponsor
- University of Eastern Finland
Thalassemia Major, Chronic Blood Transfusion Related Iron Overload
MR Imaging of Diffuse Myocardial Fibrosis in Transfusion-Dependent Anemias
Cardiac failure is the major cause of death in patients with thalassemia and chronic blood transfusion-related iron overload. The treatment of thalassemia has been revolutionized over the past decade with the implementation of…
- Trial name
- MAFIO (NCT02090699)
- Where
- Canada
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- University Health Network, Toronto
Pain Measurement, Chronic Pain
Evaluation of Chronic Postsurgical Pain Risk in Patients Undergoing CIED Implantation Using an AID Support System
Chronic postsurgical pain (CPSP) remains a significant clinical and public health challenge despite major advances in surgical and anesthetic techniques.
- Conditions
- Pain Measurement, Chronic Pain, Cardiac Implantable Electrical Devices, Neuropathic Pain
- Trial name
- PAIN-AID (NCT07322900)
- Volunteers
- 180 people
- Sponsor
- Istanbul University - Cerrahpasa
Kidney Failure, Chronic
The Clinical Evaluation of the Dose of Erythropoietins Trial
Anaemia is a risk factor for death, cardiac-cerebrovascular events and poor quality of life in patients with chronic kidney disease (CKD). Erythropoietin Stimulating Agents (ESAs) are the most used treatment option.
- Trial name
- CEDOSE (NCT00827021)
- Testing
- Erythropoiesis Stimulating Agents (ESAs): epoetin alfa, beta or any other epoetin in equivalent dose.
- Where
- 41 sites in Italy
- Volunteers
- 656 people
- Sponsor
- Giovanni FM Strippoli, MD
Heart Failure, CKD
Effect of Roxadustat on Heart Failure Patients With Anaemia and Moderate-to-Severe Chronic Kidney Disease
Previous clinical observations of potential benefit from Roxadustat in this complex patient population prompted this investigation Therefore, the investigators designed this retrospective, observational study to thoroughly…
- Conditions
- Heart Failure, CKD, Anemia
- Trial name
- NCT07268807
- Testing
- Roxadustat
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Zhongda Hospital
Chronic Obstructive Pulmonary Disease (COPD), Congestive Heart Failure (CHF)
Clinical Trials for Elderly Patients With Multiple Disease
The CHROMED project focuses its investigation on the applicability of an integrated solution for a pathological condition which: a) is very prevalent in ageing patients and b) severely impairs quality of life: COPD with other…
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD), Congestive Heart Failure (CHF), Sleep Disordered Breathing (SDB)
- Trial name
- CHROMED (NCT01960907)
- Testing
- CHROMED monitoring system
- Where
- 6 sites in Estonia, Slovenia and 3 more
- Volunteers
- 312 people
- Sponsor
- Restech Srl
Chronic Kidney Diseases, Heart Failure With Reduced Ejection Fraction
Lokelma for RAAS Maximisation in CKD & Heart Failure.
Background: CKD in patients with heart failure (HF) is common and associated with poor prognosis. Despite evidence of benefit with Renin-Angiotensin-Aldosterone-System inhibitor (RAASi) agents, they are avoided due to fear of…
- Conditions
- Chronic Kidney Diseases, Heart Failure With Reduced Ejection Fraction, Hyperkalemia, ACE Inhibitor Induced Hyperkalaemia
- Trial name
- LIFT (NCT05004363)
- Testing
- Lokelma Oral Product
- Where
- United Kingdom
- Volunteers
- 112 people
- Sponsor
- St George's, University of London
Heart Failure, Overactive Bladder
Effect of Extended Release Torsemide in Patients With Congestive Heart Failure and Overactive Bladder
This research study is being done to compare the effectiveness two drugs: an Extended Release Torsemide (ERT) versus generic Immediate Release Torsemide (IRT) in reducing the worsening of symptoms of Overactive Bladder (OAB…
- Conditions
- Heart Failure, Overactive Bladder, Incontinence
- Trial name
- NCT06206512
- Testing
- Extended release torsemide, Immediate release torsemide
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Sarfez Pharmaceuticals, Inc.
Chronic Obstructive Pulmonary Disease (COPD), Pulmonary Hypertension
Clinical Registry for the Characterization of the 'Pulmonary Vascular Phenotype' in Patients With Chronic Obstructive Pulmonary Disease
Registry of COPD (Chronic Obstructive Pulmonary Disease) patients who underwent right heart catheterization (RHC) and full clinical evaluation for pulmonary hypertension
- Trial name
- COPD-PH (NCT07102823)
- Where
- 3 sites in Austria, Switzerland and 1 more
- Volunteers
- 1,000 people
- Sponsor
- Medical University of Graz
Heart Failure, Inflammation
Efficacy of LoDoCo in Improving Exercise Capacity Among Patients With HFpEF and Inflammation
The purpose of this research study is to determine the effectiveness of low dose colchicine (LoDoCo) on measures of exercise capacity, physical function, frailty, and quality of life, among patients with heart failure with…
- Trial name
- NCT06130059
- Testing
- Low Dose Colchicine
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- University of Texas Southwestern Medical Center
Atheroma; Heart
Assessment of GARP Expression in Acute and Chronic Coronary Syndrome
The leading cause of death is cardiovascular diseases in occidental countries. Of those, atherosclerosis is the major contributor to this burden being notably responsible for strokes and myocardial infarctions.
- Trial name
- GARP-CS (NCT07384910)
- Testing
- Arterial blood sample
- Where
- Belgium
- Volunteers
- 600 people
- Sponsor
- Université Catholique de Louvain